Ramm Pharma has successfully listed on the Canadian Securities Exchange via RTO, and now trades under the symbol C:RAMM. With a recently completed raise of over $35 Million at $1.35 per share, the company opened with approximately 26 Million shares outstanding and a market cap of just over $60 Million at press time. The company has approved pharmaceutical products and is focusing on the Latin American market, a population pegged at over 600 million.
RAMM reports that it has several key strengths:
Latin America’s first registered cannabinoid pharmaceutical products
This new entrant is based in Uruguay and has an established pharmaceutical and medical product business, with 5 medical cannabis products already commercially available under two brands - Epifractá and CannabiPiel. RAMM’s products have also been approved for use on a compassionate basis in 3 other Latin American countries and are in the application process at various stages of approval in several other countries.
About Epifractán™
In 2017, Epifractán™ became the first plant-derived cannabinoid pharmaceutical drug to be approved by a Latin American federal health authority. The drug is currently sold commercially in 2% and 5% cannabidiol (CBD) concentrations. A 10% CBD concentration is in the process of being approved by the Ministry of Health (MSP). Epifractán™ is an approved treatment for refractory epilepsy with a clinical trial about to commence examining its efficacy for the treatment of chronic pain.
About CannabiPiel™
CannabiPiel™ is a cosmeceutical cream with active ingredient 1% CBD. It is available over the counter and is used for the treatment of joint pain and inflammation, as well as a variety of skin disorders and conditions. Its unique Nioskin structure makes for optimal delivery of CBD properties.
GMP certified laboratory and manufacturing facility
RAMM’s formulation and manufacturing is conducted at its Good Manufacturing Practices (GMP) certified cannabis formulation facility The facility totals approximately 36,600 sq.ft. and features dedicated cannabis and medical product laboratories along with packaging capabilities and storage/distribution facilities
In their “go public” press release, company CEO Jack Burnett “Our public listing marks a significant milestone as RAMM continues to establish itself as a leader in the development and commercialization of cannabis-derived prescription drugs and registered products to meet the growing demand in Latin America and other jurisdictions globally. We are very pleased with the interest in our suite of products and look forward to increasing access to their therapeutic benefits as we continue to expand our product offerings, awareness and availability.”
RAMM Pharma Corp. includes wholly owned subsidiaries Medic Plast SA, Yurelan SA and Ramm Pharma Holdings Corp.
Additional information about the Company is available at www.rammpharma.com.
FULL DISCLOSURE: RAMM Pharma Corp. is a client of Stockhouse Publishing.